Alkermes Pharma Ireland Limited

Elan Pharma International Limited

Jon Swanson

Rajeev A Jain

Gary G Liversidge

John G Devane

Maurice Joseph Anthony Clancy

Janet Elizabeth Codd

Robert Hontz

H William Bosch

Niels Peter Ryde

Kenneth Iain Cumming

Linden Wei

Kenneth Ian Cumming

Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.

Controlled-release nanoparticulate compositions

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

Glipizide compositions

Described are solid dose nanoparticulate naproxen formulations having high rates of dissolution. The solid dose nanoparticulate naproxen formulations can comprise an alkali compound, which functions to increase the dissolution rate of the naproxen following administration. Alternatively, the solid dose nanoparticulate naproxen formulation can comprise an alkali compound and an acidic compound, which can react together to form carbon dioxide. The formed carbon dioxide can also aid in increasing the dissolution rate of the naproxen following administration. Also described are solid dose nanoparticulate naproxen formulations having a decreased concentration of a binder/disintegrant agent. Such compositions also provide an increased rate of dissolution of naproxen following administration.

Solid dose form of nanoparticulate naproxen

Growing community of inventors

North Wales, PA, United States of America

Jon Swanson